Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | CCR1 | P32246 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6141793 | 0.76 | ALDH1A1 (0.47) | ALDH1A1RAB9ACCR1PKMMAPT | |
| SCHEMBL13348713 | 0.75 | EPHX1 (0.51) | ALDH1A1RAB9ACCR1PKMEPHX1 | |
| SCHEMBL6928586 | 0.75 | HDAC3 (0.54) | ALDH1A1RAB9ACCR1PKMEPHX1 | |
| SCHEMBL6719649 | 0.74 | ALDH1A1 (0.43) | ALDH1A1RAB9ACCR1MAPTEPHX2 | |
| SCHEMBL25464076 | 0.70 | MAPT (0.46) | ALDH1A1RAB9ACCR1PKMMAPT | |
| SCHEMBL10639153 | 0.69 | PKM (0.46) | ALDH1A1RAB9ACCR1PKMEPHX1 | |
| SCHEMBL11582899 | 0.69 | CCR1 (0.53) | ALDH1A1RAB9ACCR1PKMEPHX1 | |
| SCHEMBL27769526 | 0.68 | HDAC3 (0.43) | RAB9ACCR1MAPTSMN1; SMN2CHRM2 | |
| SCHEMBL27481076 | 0.67 | HDAC3 (0.59) | RAB9ACCR1SMN1; SMN2LMNACHRM2 | |
| SCHEMBL28248578 | 0.67 | RAB9A (0.55) | ALDH1A1RAB9APKMEPHX1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005047253-A1 | MELANOCORTIN RECEPTOR AGONISTS | LG LIFE SCIENCES LTD. (KR) | 2005-05-26 | — | — | WO | disclosed |
| US-20050014816-A1 | Thiophene amino acid derivatives, process for preparing them and pharmaceutical compositions containing them | PFIZER INC | 2005-01-20 | — | — | US | disclosed |
| WO-2005003115-A1 | THIOPHENE AMINO ACID DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | WARNER-LAMBERT COMPANY LLC (US) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014816-A1 | Thiophene amino acid derivatives, process for preparing them and pharmaceutical compositions containing them | MMP12, MMP9, MMP13 | ALDH1A1 3564/4885RAB9A 475/4885CCR1 374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.